CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 10 enrolled
Drug / intervention
Dexamethasone 2.5 mg and Sitagliptin 100 mg +1 moredrug
Likely dose
Dexamethasone 2.5 mg and Sitagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01488279
NCT01488279N/ACompleted
CompareCT.gov

Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy

University of Vermont·interventional·Posted Dec 8, 2011·Updated Mar 12, 2018

In Brief

A clinical study evaluating Dexamethasone 2.5 mg and Sitagliptin 100 mg and Dexamethasone 2.5 mg and placebo tablet for Pre-diabetes and 2 related conditions. Completed, enrolled 10 participants across 1 site.

Detailed Summary

The investigators hypothesize that sitagliptin will significantly reduce impairments in insulin secretion and insulin resistance resulting from short-term oral glucocorticoid therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPre-diabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 8, 2011
Enrollment StartSep 1, 2012
Primary CompletionJul 1, 2014
Study CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.6 years ago

Interventions

Dexamethasone 2.5 mg and Sitagliptin 100 mgdrug

Participants received Dexamethasone 2.5mg plus Sitaliptin 100mg daily for 8 days

Dexamethasone 2.5 mg and placebo tabletdrug

Participants rececived Dexamethasone 2.5 mg plus placebo tablet daily for 8 days